We evaluated the effectiveness of sildenafil citrate on lower urinary system symptoms (LUTS) by using symptom score scales. We also evaluated whether or not the presence of asymptomatic inflammatory prostatitis had an effect on the alteration in the symptom scores. A total of 36 male patients were included in the study. For all the cases, 'International Prostate Symptom Score' (IPSS), 'National Health Institute Chronic Prostatitis Symptom Index' (NIH-CPSI) and 'International Index of Erectile Function' (IIEF-5) were investigated and the scores were calculated in the first visit. Sildenafil citrate was given for 30 days and at the second visit IPSS, NIH-CPSI and IIEF-5 scores were once more analyzed. Afterwards, the alterations of the scores between visits were statistically compared. Mean age of the 36 cases included in the study was 59.03 ± 1.35. When the alterations in parameters of first visit and second visit were evaluated, we found a statistically significant increase in IIEF-5 and a statistically significant decrease in IPSS, IPSS-QOL (Quality of Life). In addition, when the cases were divided into two groups with and without asymptomatic inflammatory prostatitis, in the cases with asymptomatic inflammatory prostatitis, sildenafil citrate caused improvement only in ED, but had no effect on LUTS. Sildenafil citrate use in cases with LUTS and ED has an improving effect on LUTS as well as ED. However, in cases with asymptomatic inflammatory prostatitis, sildenafil citrate did not lead to an improvement in LUTS.
Introduction
Recently, a growing attention is being paid to the relation between lower urinary system symptoms (LUTS) and sexual dysfunction. The relation between LUTS and sexual dysfunction is confirmed by 'Multinational Survey of the Aging Male-7' (MSAM-7), without any shadow of doubt. 1 It suggests that the two conditions have a common initiator factor and a link is present between their cause-outcome relations. 2 Some evidence shows that LUTS and ED are developed by similar pathophysiological mechanisms. Both conditions occur as a result of cellular and molecular changes related to age. Probably, the future studies will provide valuable data for the development of more effective and corporate methods in the treatment of age-related disorders. If LUTS/benign prostatic hyperplasia (BPH) and male sexual dysfunction share a common pathophysiological mechanism, to use a single optimal medical strategy might be possible. Preclinical and clinical data suggest that PDE5 inhibitors, which are first-line treatment for ED, may be considered as promising drugs for treating LUTS/BPH. 3 In future, a single agent or combined therapies will be able to find a place in the treatment of both conditions. 4 Although an association has repeatedly been shown between LUTS and ED, little is known regarding the impact of chronic prostatitis (CP) on ED. 5 Although there are articles underlining the link between CP and ED, its reason could not be clearly explained. It is suggested that, quality of life and psychological status of the patients are generally affected due to pain and voiding dysfunction in patients with CP/chronic pelvic pain syndrome, and it has a negative influence on sexual functions. 6, 7 Interestingly, in many asymptomatic patients who do not have CP diagnosis, significant leukocytes and bacteria are found in EPS (expressed prostatic secretions) and postprostatic massage urine sediment. These patients are classified as category IV prostatitis (asymptomatic inflammatory prostatitis) according to NIH classification. Besides, asymptomatic inflammatory prostatitis is a common pathological finding in patients with BPH. However, the clinical importance of this finding is not well understood. The origin of inflammation in the prostate remains a subject of debate and is likely multifactorial. 8 Our aim of designing this study was to evaluate the medical therapy outcomes of LUTS/BPH and ED, which we thought to be inter-related and the effects of sildenafil citrate on LUTS, by using symptom score scales. In addition, whether or not the presence of asymptomatic inflammatory prostatitis had an effect on the change of these symptom scores was investigated.
Materials and methods
A total of 36 males were included in this study, who attended to our clinic because of ED along with LUTS. All of the cases were sexually active. The cases with acute urinary system infection, CP/chronic pelvic pain syndrome, urogenital system tumor, previous urogenital system surgery, neurogenic bladder, urethral stenosis, bladder stone, overactive bladder and that use 5-a-reductase inhibitors were not included in the study. In addition, the cases that sildenafil citrate was contraindicated were excluded. Local ethical approval was obtained from our Hospital Ethics Committee, all patients were informed about the study and gave their informed consent before their inclusion in the study. We respected to the 'Code of Ethics of the World Medical Association' during all the study period.
In the initial visit, detailed anamnesis was taken from all the cases included in the study and physical examinations were done. Urine samples were obtained for whole urine analysis and urine culture. Serum samples were taken for biochemical examination and determination of total PSA (prostate-specific antigen) level. The patients with total PSA level 42.5 ng/ml were placed into prostate biopsy program and excluded from the study. In addition, 4-glass test was performed for all patients. The secretion obtained by prostate massage (EPS) and urine obtained after massage (VB3) was investigated by culture and direct microscopic examination. Patients were classified as category IV prostatitis (asymptomatic inflammatory prostatitis) by the presence of significant leukocytes (or bacteria or both) in EPS or VB3 in the absence of typical chronic pelvic pain. 9 Urinary system was examined by kidney, ureter, bladder radiographic imaging and pelvic ultrasonography. Prostate volume and postvoid residual (PVR) urine amount was measured by pelvic ultrasonography. Furthermore, maximum flow rates (Qmax) of all the cases were evaluated by uroflowmetry.
All the cases included in the study were questioned in the first visit using 'International Prostate Symptom Score' (IPSS), 'National Health Institute Chronic Prostatitis Symptom Index (NIH-CPSI) and 'International Index of Erectile Function' (IIEF-5) questionnaires and the scores were calculated. [10] [11] [12] The patients with IPSS score 47 and IIEF-5 score o22 were included in the study. The cases with IPSS score between 8 and 19 were considered as having moderate, between 20 and 35 severe LUTS. The cases with IIEF-5 score between 17 and 21 had mild, between 12 and 16 had mild-moderate, between 8 and 11 had moderate and between 5 and 7 had severe ED. Based on total NIH-CPSI scoring CP severity was classified as mild (0-14), moderate (15-29) and severe (30 or greater). 6 Sildenafil citrate (Viagra s , Pfizer, NY, USA) was started (50 mg, twice weekly) to all the cases in the first visit. During the study, patients received 50 mg sildenafil citrate for twice a week and had sexual intercourse for at least two times in a week. The patients were trained about the drug usage protocol, duration of the drug effect and side effects. The patients who were unable to carry out the study protocol, were excluded. The patients used sildenafil citrate for 30 days and came for the second visit. Then, IPSS, NIH-CPSI, IIEF-5 scores and Qmax, as well as PVR were determined once more. Consequently, the alterations between scores of the both visits were compared.
For the statistical analysis of the study data, Graphpad prism 5.0 programme (GraphPad Software, CA, USA) was used. Besides descriptive statistical methods (mean, s.d.), one-way ANOVA, Kruskal-Wallis, Mann-Whitney and paired t-tests were used for the comparison of quantitative data. The results were evaluated at 95% confidence interval and significance level of Po0.05.
Results
Mean age of the 36 cases included in the study was 59.03 ± 1.35 years. General characteristics of the cases as well as mean symptom scores are presented in Table 1 . When the cases were evaluated according to IIEF-5 scores, there was mild ED in 6 (16.7%), mild-moderate ED in 8 (22.2%), moderate ED in 12 (33.3%) and severe ED in 10 (27.8%) cases. When the IPSS scores of the cases separated according to ED intensity were assessed, any significant difference was not found between groups (Table 2) .
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In the 36 patients included in the study, 1 had flushing and 2 had dyspepsia due to medication, however, these side effects were minimal and the patients were not excluded.
When the alterations in parameters of first visit and second visit, which was done at day 30 of sildenafil citrate use were compared; there was a statistically significant increase in IIEF-5, a statistically significant decrease in IPSS, IPSS-QOL (Po0.05). However, there wasn't any statistically significant change in NIH-CPSI, Qmax and PVR (Table 3) .
The cases were separated into two groups as the ones with asymptomatic inflammatory prostatitis (n ¼ 14) and the ones without asymptomatic inflammatory prostatitis (n ¼ 22), and the changes between first and second visit were compared. There wasn't any statistically significant difference between groups regarding age and BMI levels. When we evaluated prostate volume, it was 33.71±4.59 in the group with asymptomatic inflammatory prostatitis and 33.36 ± 2.62 in the group without asymptomatic inflammatory prostatitis. A statistically significant difference was not found between groups (P ¼ 0.84). IIEF-5 was increased, IPSS, IPSS-QOL, NIH-CPSI scores were decreased and Qmax and PVR were not changed in cases without asymptomatic inflammatory prostatitis (Table 4) . When the parameters between first and second visits were compared in cases with asymptomatic inflammatory prostatitis, there was a statistically significant increase in only IIEF-5 (Po0.05). No statistically significant alteration was observed in IPSS, IPSS-QOL, NIH-CPSI, Qmax and PVR (Table 5) .
In summary, when the patients were separated into two groups as the ones with and without asymptomatic inflammatory prostatitis, IIEF-5 score increased, IPSS, IPSS-QOL, NIH-CPSI scores decreased in the patients without asymptomatic 
Discussion
Many epidemiological studies prove that LUTS and sexual dysfunction are strongly associated. Both diseases have high prevalence and grave negative effects on the quality of life. 13 Might both diseases have a single etiological mechanism or are there more than one mechanisms, some with indirect effects?
In the Multinational Survey of the Aging Male-7 study that included 14 000 males from six European countries and USA aged between 50 and 80 years, the relation between LUTS and sexual dysfunction was confirmed without doubt. 1 Even though the epidemiological studies showed a powerful relation between LUTS and ED, they do not satisfactorily answer the questions regarding the underlying pathology. If there is a relation between LUTS and sexual dysfunction, to clarify the specific underlying mechanisms will have a significant effect on determining the diagnosis and treatment of these disorders. The leading theories try to explain the mechanism by the over activity of autonomic nervous system, endothelial function alterations occurred because of the effects on nitric oxidecyclic guanosin monophosphate pathway and the alterations on Rho-kinase pathway. 14 PDE5 inhibitor-mediated smooth muscle relaxation occurs not only in corpus cavernosum, but also in the bladder neck, urethra and prostate. These findings support the possible use of PDE5 inhibitors for treating LUTS secondary to BPH. The validity of this hypothesis has been further substantiated by preclinical and clinical studies. Also, we think that the effect of sildenafil citrate is possibly a result of smooth muscle relaxation in lower urinary tracts caused by sildenafil. 4 There are many studies in literature supporting our findings. [15] [16] [17] In all those studies, questionnaires (IPSS, IPSS-QOL) were used while examining the effect of PDE5 inhibitors on LUTS and it was evaluated whether or not a statistically significant decrease was present. However, the rate of patients who responded to therapy was not given in those studies.
Although the relation between LUTS and ED is mentioned in many articles, the link between CP and ED is not clearly explained. Liang et al. 18 investigated the relationship between CP and sexual dysfunction and they found approximately 49% of the patients with CP had sexual dysfunction. Tuncel et al. 19 observed that sexual dysfunction is the most common symptom in patients with prostatic inflammation. Therefore, prostatic inflammation should be considered in differential diagnosis in patients who have sexual dysfunction. The prevalence of sexual dysfunction in men with CP is high, but the underlying reason is not well defined. The relevant studies generally showed that quality of life was affected because of pain in patients with CP/chronic pelvic pain syndrome. Besides, emotional discomfort due to pain and voiding dysfunction also negatively affects the sexual functions. 8, 20, 21 Prostatic inflammation is a common feature of the adult prostate and is associated with the development and progression of BPH. Asymptomatic inflammatory prostatitis is observed in high amounts in the pathological examination of prostate biopsies or prostate tissues taken after prostatic surgery. 22, 23 There is not enough data about clinical importance of this finding. Ozden et al. 24 reported that high serum PSA levels may correlate with asymptomatic inflammatory prostatitis. In a recent analysis of the data from the REDUCE trial, Nickel et al. reported statistically significant association between chronic prostatic inflammation and LUTS severity. 25 According to this study, chronic inflammation accompanying BPH may sensitize afferent nerve fibers of the bladder, resulting in development of LUTS. The role of prostatic inflammation and afferent sensitization is not well understood.
Our aim of designing this study was to investigate the effects of sildenafil citrate on LUTS besides ED in the medical treatment of LUTS/BPH and ED, which we believed to be interrelated, by using symptom score scales. If the presence of asymptomatic inflammatory prostatitis in those cases had an influence on the change of symptom scores, which was also investigated.
In our study, there was an increase in IIEF-5 scores and decrease in IPSS, IPSS-QOL scores following sildenafil citrate therapy given for 30 days twice a week. A significant change was not observed in NIH-CPSI score, Qmax and PVR. In other words, sildenafil citrate improved LUTS, as well as ED. However, this improvement was seen only as a decrease in IPSS and IPSS-QOL scores. It was not supported by an improvement in NIH-CPSI score, Qmax and PVR.
Another issue we questioned in our study was whether or not the presence of asymptomatic inflammatory prostatitis had an effect on response to sildenafil citrate. IIEF-5 scores increased and IPSS, IPSS-QOL, NIH-CPSI scores decreased in cases without asymptomatic inflammatory prostatitis, whereas Qmax and PVR did not significantly alter. However, in the cases with asymptomatic inflammatory prostatitis only IIEF-5 significantly increased after sildenafil citrate. IPSS, IPSS-QOL, NIH-CPSI, Qmax and PVR did not change significantly. That is, in the cases with asymptomatic inflammatory prostatitis compared with the cases Sildenafil use in cases with LUTS and ED B Eryildirim et al without asymptomatic inflammatory prostatitis, sildenafil citrate caused improvement only in ED, but had no effect on LUTS. It is not very clear that why sildenafil citrate does not has effect on ED in patients with asymptomatic inflammatory prostatitis and there is not any study about the mechanism of this subject in literature. We think that, inflammation induced cytokine activation modifies the production/activity of vasodilatory mediators such as nitric oxide. Thus, asymptomatic inflammatory prostatitis might affect smooth muscle relaxation in lower urinary tracts caused by sildenafil. 26 In addition, chronic inflammation of prostate might impair microvascularization of the prostate. Therefore, sildenafil citrate had no effect on LUTS in these cases.
Our study has some limitations. One of them is the lack of a placebo arm in the study design. Also, the study is not randomized and the sample size is small. Besides, after the treatment of CP patients, response to sildenafil could be examined once again. However, we found that sildenafil citrate improved LUTS as well as ED in patients with LUTS and ED, although it did not lead to an improvement in LUTS in patients with asymptomatic inflammatory prostatitis. This result is interesting and may be clinically significant. To search CP presence in patients with LUTS and ED who do not respond to PDE5 inhibitors and give therapy if CP is found may contribute to ED treatment.
Conclusion
Sildenafil citrate use in the cases with LUTS/BPH and ED showed improvement on ED along with LUTS. Yet, in cases with asymptomatic inflammatory prostatitis, sildenafil citrate did not lead to an improvement in LUTS. Asymptomatic inflammatory prostatitis should be searched in ED patients who do not respond to PDE5 inhibitors. In these cases, treatment of CP might diminish the complaints of LUTS and ED. In order to develop optimal treatment strategies in the patients with LUTS/BPH and ED, well-designed, large-scaled prospective studies should be planned.
